Poll Results Punctuate Key Lung Cancer Abstracts Driving Intrigue Ahead of ASCO 2025

In the lead-up to the 2025 ASCO Annual Meeting, anticipation is building around several key datasets poised to shape the next chapter of lung cancer care.

To gauge expert interest ahead of the conference, OncLive® polled lung cancer specialists on X to identify which high-impact presentations they were most eager to learn about during the meeting. Results from 9 responses revealed clear frontrunners, with late-breaking abstracts LBA8010 and LBA8000 capturing the most attention (33.3%), followed by abstracts 8015, 8639, 8001, and LBA8505 (22.2%); abstract 8500 (22.2%); and abstract 8646 (22.2%). On LinkedIn, LBA8010 and LBA8000; abstracts 8015, 8639, 8001, and LBA8505; and abstract 8500 all received 1 vote (33%).

OncLive also asked which treatment strategies for NSCLC they were most interested to learn more about during ASCO. Among 37 responders on X, 37.8% selected targeted therapy plus immuno-oncology (IO); 32.4% voted for targeted therapy regimens; 16.2% selected perioperative IO approaches; and 13.5% selected rechallenging with targeted therapy. Among 59 responders on LinkedIn, the rates of these responses were 41%, 20%, 25%, and 14%, respectively

Below is a detailed breakdown of the most anticipated abstracts, based on the poll results, along with a summary of trial design, prior findings, and associated regulatory decisions.

LBA8010: Perioperative nivolumab (NIVO) vs placebo (PBO) in patients (pts) with resectable NSCLC: Updated survival and biomarker analyses from CheckMate 77T.

Presentation time: Sunday, June 1, 4:36pm – 4:42pm CDT

The phase 3 CheckMate 77T trial (NCT04025879) is a pivotal, randomized, double-blind, multicenter study evaluating the addition of neoadjuvant nivolumab (Opdivo) to platinum-doublet chemotherapy followed by surgery and adjuvant nivolumab vs neoadjuvant chemotherapy plus placebo followed by surgery and adjuvant placebo in patients with stage IIA to IIIB resectable non–small cell lung cancer (NSCLC).¹

Previously reported data from the study supported the October 2024 FDA approval of perioperative nivolumab in combination with platinum-doublet chemotherapy for adult patients with resectable NSCLC without EGFR mutations or ALK rearrangements. Prior data showed that the median event-free survival (EFS) was not reached (NR) in the nivolumab arm vs 18.4 months in the chemotherapy arm (HR, 0.58; 95% CI, 0.43-0.78; P = .00025). At the time of prespecified interim analysis, overall survival (OS) was not formally tested for statistical significance, although no detriment was observed in descriptive analyses.

LBA8000: Overall survival with neoadjuvant nivolumab (NIVO) + chemotherapy (chemo) in patients with resectable NSCLC in CheckMate 816.

Presentation time: Monday, June 2nd, 3:00pm – 3:12pm CDT

The phase 3 CheckMate 816 trial (NCT02998528) evaluated the efficacy of neoadjuvant nivolumab combined with chemotherapy vs chemotherapy alone in patients with stage IB to IIIA resectable NSCLC without known EGFR or ALK alterations; based on prior results, the combination was approved by the FDA on March 4, 2022, for the neoadjuvant treatment of patients with resectable NSCLC.²

Initial data showed that the median EFS was 31.6 months (95% CI, 30.2-NR) with the combination vs 20.8 months (95% CI, 14.0-26.7) with chemotherapy alone (HR, 0.63; 97.38% CI, 0.43-0.91; P = .0052). Additionally, the pathological complete response (pCR) rate was 24% (95% CI, 18.0%-31.0%) in the nivolumab group compared with 2.2% (95% CI, 0.6%-5.6%) in the chemotherapy-only group.

According to a press release from Bristol Myers Squibb in February 2025, treatment with this regimen led to statistically significant and clinically meaningful improvement in OS vs neoadjuvant chemotherapy alone in patients with resectable NSCLC.³

LBA8505: Savolitinib (Savo) combined with osimertinib (osi) versus chemotherapy (chemo) in EGFR-mutant (EGFRm) and MET-amplification (METamp) advanced NSCLC after disease progression (PD) on EGFR tyrosine kinase inhibitor (TKI): Results from a randomized phase 3 SACHI study.
Presentation time: Sunday, June 1st, 9:48am – 10:00am CDT

The multicenter, controlled, open-label, phase 3 SACHI trial (NCT05015608) evaluated savolitinib (Orpathys) plus osimertinib (Tagrisso) vs platinum-based chemotherapy in patients with EGFR-mutated, MET-amplified advanced NSCLC who had progressed on a prior EGFR TKI.⁴ The primary end point was investigator-assessed PFS, with secondary end points including OS, overall response rate (ORR), duration of response (DOR), disease control rate (DCR), time to response, and safety.

Interim results from the SACHI trial indicated that the combination therapy met its predefined PFS end point.⁵ As a result, China's National Medical Products Administration granted priority review to the new drug application seeking the approval of the savolitinib and osimertinib combination for the treatment of this patient population in January 2025.

8015: Alectinib as neoadjuvant treatment in potentially resectable stage III ALK-positive NSCLC: Final analysis of ALNEO phase II trial (GOIRC-01-2020-ML42316).

Presentation time: Sunday, June 1st, 5:30pm – 5:36pm CDT

The open-label, single-arm, multicenter, phase 2 ALNEO trial (NCT05015010) investigated the use of alectinib (Alecensa) as neoadjuvant therapy in previously untreated patients with potentially resectable, stage III ALK-positive NSCLC.⁶ The primary end point was major pathological response (MPR), with secondary end points including pCR rate, ORR, EFS, DFS, OS, and safety.

8639: Amivantamab plus chemotherapy vs chemotherapy in EGFR-mutant advanced NSCLC after disease progression on osimertinib: Outcomes by osimertinib resistance mechanisms in MARIPOSA-2.

Poster session: Saturday, May 31st, 1:30pm CDT

The phase 3 MARIPOSA-2 trial (NCT04988295) evaluated the combination of amivantamab-vmjw (Rybrevant) plus carboplatin and pemetrexed vs chemotherapy alone in 295 patients with advanced EGFR-mutant NSCLC who had progressed on prior osimertinib.⁷ The primary end point of the trial was PFS, with secondary end points including ORR, OS, and safety.

Prior data from this trial led to the FDA approval of amivantamab plus chemotherapy in this patient population in September 2024.⁸ Updated findings from MARIPOSA presented during the 2025 European Lung Cancer Congress showed that at a median follow-up of 37.8 months, the median OS with the doublet (n = 429) was NR (95% CI, 42.9-NR) vs 36.7 months (95% CI, 33.4-41.0) with osimertinib (n = 429), translating to a 25% reduction in the risk of death (HR, 0.75; 95% CI, 0.61-0.92; P < .005).⁷

8001: Neoadjuvant (neoadj) osimertinib (osi) ± chemotherapy (CT) vs CT alone in resectable (R) epidermal growth factor receptor-mutated (EGFRm) NSCLC: NeoADAURA.

Presentation time: Monday, June 2nd, 3:12pm CDT

The phase 3 NeoADAURA trial (NCT04351555) is a randomized, multicenter study evaluating neoadjuvant osimertinib, with or without chemotherapy, vs chemotherapy alone in patients with resectable, stage II to IIIB EGFR-mutant NSCLC.⁹ The primary end point was MPR, and secondary end points included EFS, pCR rate, nodal downstaging, DFS, OS, and safety.

Prior findings found that among the 24 patients who underwent surgical resection, the MPR rate was 14.8% (95% CI, 4.2%-33.7%), which did not meet the predefined threshold of 50%. No pCRs were observed. The ORR was 52%, and the median DFS was 40.9 months. Importantly, no patients experienced delays in surgery or became ineligible for surgery due to toxicities.

8500: First-line adagrasib (ADA) with pembrolizumab (PEMBRO) in patients (pts) with advanced/metastatic KRASG12C-mutated non-small cell lung cancer (NSCLC) from the phase 2 portion of the KRYSTAL-7 study.

Presentation time: Sunday, June 1st, 8:00am – 8:12am

The phase 2 KRYSTAL-7 study (NCT04613596) is a multicenter trial evaluating adagrasib (Krazati) plus pembrolizumab (Keytruda) as a first-line treatment for patients with advanced or metastatic, KRAS G12C–mutated NSCLC.¹⁰ The primary end point of the study was investigator-assessed ORR by RECIST 1.1 crtieria; secondary end points included investigator-assessed DOR and PFS, OS, and safety.

Findings presented during the 2025 European Lung Cancer Congress showed that, in the phase 2 KRYSTAL-7 cohort, the ORR was 59% (95% CI, 45.0%-72.4%) with a median DOR of 26.3 months (95% CI, 26.3-not evaluable [NE]). Moreover, the median PFS at a median follow-up of 22.6 months was 27.7 months (95% CI, 8.1-NE).

8646: Rechallenge with first-generation RET inhibitors in RET-rearranged NSCLC pre-treated with selpercatinib or pralsetinib: Results from the RET MAP registry.

Poster session: Saturday, May 31st, 1:30pm CDT

The RET MAP registry is an international, multicenter, retrospective study collecting real-word data from a total of 218 patients with NSCLC harboring a RET fusion who were diagnosed between February 2012 and April 2022.¹¹ This analysis will evaluate the efficacy and safety of rechallenging patients with RET fusion-positive NSCLC who had previously progressed on selpercatinib (Retevmo) or pralsetinib (Gavreto). Clinicobiological features and treatment outcomes across multiple therapies, including surgery, chemotherapy (CT), immune checkpoint inhibitors (ICIs), combination CT-ICI, multi-TKIs, and RET inhibitors, were analyzed.

References

1. FDA approves neoadjuvant/adjuvant nivolumab for resectable non-small cell lung cancer. FDA. October 3, 2024. Accessed May 9, 2025. https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-neoadjuvantadjuvant-nivolumab-resectable-non-small-cell-lung-cancer
2. FDA approves neoadjuvant nivolumab and platinum-doublet chemotherapy for early-stage non-small cell lung cancer. FDA. March 4, 2022. Accessed May 9, 2025. https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-neoadjuvant-nivolumab-and-platinum-doublet-chemotherapy-early-stage-non-small-cell-lung
3. Bristol Myers Squibb announces Opdivo plus chemotherapy as the first and only neoadjuvant-only immuno-oncology therapy to demonstrate statistically significant and clinically meaningful overall survival in resectable non-small cell lung cancer. News release. Bristol Myers Squibb. February 19, 2025. Accessed May 9, 2025. https://news.bms.com/news/corporate-financial/2025/Bristol-Myers-Squibb-Announces-Opdivo-Plus-Chemotherapy-as-the-First-and-Only-Neoadjuvant-Only-Immuno-Oncology-Therapy-to-Demonstrate-Statistically-Significant-and-Clinically-Meaningful-Overall-Survival-in-Resectable-Non-Small-Cell-Lung-Cancer/default.aspx
4. Study on savolitinib combined with osimertinib in treatment of advanced NSCLC with MET amplification (SACHI). ClinicalTrials.gov. Updated March 30, 2023. Accessed May 9, 2025. https://clinicaltrials.gov/study/NCT05015608
5. HUTCHMED Announces NDA acceptance in China with priority review status for Orpathys and Tagrisso combination in lung cancer patients with MET amplification after progression on first-line EGFR inhibitor therapy. News release. HUTCHMED. January 2, 2025. Accessed May 9, 2025. https://www.hutch-med.com/orpathys-tagrisso-nda-acceptance-in-china-with-priority-review-status-for-lung-cancer-after-egfri/
6. Leonetti A, Boni L, Gnetti L, et al. Neoadjuvant alectinib in potentially resectable stage III ALK-Positive NSCLC: Interim analysis of ALNEO-GOIRC-01-2020 phase II trial. J Thor Oncol. 2024;19(10):S52. doi:10.1016/j.jtho.2024.09.091.
7. RYBREVANT (amivantamab-vmjw) plus LAZCLUZE (lazertinib) outperforms osimertinib with a significant and unprecedented overall survival benefit in patients with EGFR-mutated non-small cell lung cancer. News release. Johnson & Johnson. March 26, 2025. Accessed May 9, 2025. https://www.jnj.com/media-center/press-releases/rybrevant-amivantamab-vmjw-plus-lazcluze-lazertinib-outperforms-osimertinib-with-a-significant-and-unprecedented-overall-survival-benefit-in-patients-with-egfr-mutated-non-small-cell-lung-cancer
8. Rybrevant (amivantamab-vmjw) plus Lazcluze (lazertinib) approved in the U.S. as a first-line chemotherapy-free treatment for patients with EGFR-mutated advanced lung cancer. News release. Johnson & Johnson. August 20, 2024. Accessed May 9, 2025. https://www.investor.jnj.com/news/news-details/2024/RYBREVANT-amivantamab-vmjw-plus-LAZCLUZE-lazertinib-approved-in-the-U.S.-as-a-first-line-chemotherapy-free-treatment-for-patients-with-EGFR-mutated-advanced-lung-cancer/default.aspx
9. Blakely CM, Urisman A, Gubens MA, et al. Neoadjuvant Osimertinib for the Treatment of Stage I-IIIA Epidermal Growth Factor Receptor-Mutated Non-Small Cell Lung Cancer: A Phase II Multicenter Study. J Clin Oncol. 2024;42(26):3105-3114. doi:10.1200/JCO.24.00071
10. First-line adagrasib (ADA) with pembrolizumab (PEMBRO) in patients with advanced/metastatic KRASG12C-mutated non-small cell lung cancer (NSCLC) and PD-L1 ≥ 50% from the phase 2 portion of KRYSTAL-7. Presented at: 2025 European Lung Cancer Congress; March 26-29, 2025; Paris, France. Abstract 5MO.
11. Aldea M, Marinello A, Duruisseaux M, et al. RET-MAP: An International Multicenter Study on Clinicobiologic Features and Treatment Response in Patients With Lung Cancer Harboring a RET Fusion. J Thorac Oncol. 2023;18(5):576-586. doi:10.1016/j.jtho.2022.12.018